Xiaoqi Liu
Corporate Officer/Principal bei Trialspark, Inc.
Profil
Xiaoqi Liu is currently the Director & Business Development at Formation Bio Inc since 2023.
Prior to this, he worked as Director & Business Development at Halozyme Therapeutics, Inc. from 2021 to 2022 and as Director, Strategy & Corporate Development at Gelesis, Inc. from 2020 to 2021.
Liu completed his graduate degree at Northwestern University and his undergraduate degree at Beijing Normal University.
Aktive Positionen von Xiaoqi Liu
| Unternehmen | Position | Beginn |
|---|---|---|
Trialspark, Inc.
 Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | Corporate Officer/Principal | 01.01.2023 |
Ehemalige bekannte Positionen von Xiaoqi Liu
| Unternehmen | Position | Ende |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2022 |
| GELESIS INC | Corporate Officer/Principal | 01.12.2021 |
Ausbildung von Xiaoqi Liu
| Northwestern University | Graduate Degree |
| Beijing Normal University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Trialspark, Inc.
Trialspark, Inc. Investment ManagersFinance Trialspark, Inc(Trialspark) is a Private Equity firm founded in 2013 by Benjamine Liu, Kit Dobyns, and Linhao Zhang. The firm is headquartered in New York, US. | Finance |
Gelesis, Inc.
 Gelesis, Inc. BiotechnologyHealth Technology Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA. | Health Technology |
